References
1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
2. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
3. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
4. Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP, Vlachopoulos C. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2024;10:403-412.
5. Corbic M, Sretenovic J, Zivkovic V, Jakovljevic V, Nikolic Turnic T. Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review. Iran J Public Health 2023;52:870-9.
6. Abouelmagd ME, Abdelmeseh M, Elrosasy A, et al. Phosphodiesterase-5 inhibitors use and the risk of alzheimer’s disease: a systematic review and meta-analysis. Neurol Sci 2024; 45:5261-70.
7. Kumar A, Kim F, Song DK, Choung JJ. Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders. Aging Dis 2024;15:2008-14.
8. Roy S, Kloner RA, Salloum FN, Jovin IS. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovasc Drugs Ther 2023;37:793-806.
9. Andersson DP, Landucci L, Lagerros YT, et al. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. J Am Coll Cardiol 2021;77:1535-50.
10. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008;29:1681-7.
11. Carella MC, Forleo C, Stanca A, et al. Heart Failure and Erectile Dysfunction: a Review of the Current Evidence and Clinical Implications. Curr Heart Fail Rep 2023;20:530-41.
12. Xanthopoulos A, Wolski K, Wang Q, et al. Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices. JACC Heart Fail 2022;10:89-100.
13. Galiè N, Barberà JA, Frost AE, et al. AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.N Engl J Med 2015;373:834-44.
14. Grünig E, Jansa P, Fan F, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2024;83:473-84.
15. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors. J Am Coll Cardiol 2024;83:417-26.
16. AlRuwaili R, Al-Kuraishy HM, Alruwaili M, et al. The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS). Mol Cell Biochem 2024;479:1267-78.
17. Benza RL, Grünig E, Sandner P, Stasch JP, Simonneau G. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Eur Respir Rev 2024;33:230183.
18. Ahmad N, Wang Y, Ali AK, Ashraf M.Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. Am J Physiol Heart Circ Physiol 2009;297:H387-91.
19. Nagiub M, Filippone S, Durrant D, Das A, Kukreja RC.Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. Can J Physiol Pharmacol 2017;95:295-304.
20. Xiao J, Zhang N, Gao Z, et al. Phosphodiesterase 5 and its inhibitors with ischemic heart disease: a Mendelian randomization analysis and a real-world study. Eur Heart J Cardiovasc Pharmacother 2024; pvae081. doi: 10.1093/ehjcvp/pvae081.
21. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease.Eur Heart J 2014;35:1917-24.
22. Larsson SC, Butterworth AS, Burgess S.Mendelianrandomization for cardiovascular diseases: principles and applications. Eur Heart J 2023;44:4913-24.
23. Bermejo J, Yotti R, García-Orta R, et al. Sildenafil for Improving Outcomes after VAlvular Correction (SIOVAC) investigators. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018;39:1255-64.
24. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015;36:2565-73.
25. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
26. Etminan M, Sodhi M, Mikelberg FS, Maberley D. Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US. JAMA Ophthalmol 2022;140:480-4.
27. Stridh A, Pontén M, Arver S, Kirsch I, Abé C, Jensen KB. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e201423.
28. Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJ. The Role ofPDE5 Inhibitors and the NO/cGMP Pathway in Cancer. Sex Med Rev 2016;4:74-84.
29. Sanati M, Aminyavari S, Mollazadeh H, Bibak B, Mohtashami E, Afshari AR. How dophosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme. Pharmacol Rep 2022;74:323-39.
30. Sharpe BP, Hayden A, Manousopoulou A, et al. Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. Cell Rep Med 2022;3:100541.
31. Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
32. Hu C. Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine. Clin Complement Med Pharmacol 2023;3:100089.
33. Hu C. Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease. Nat Prod Bioprospect 2024;14:12.
34. Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med 2024;21:90-116.
35. Vestergaard N, Søgaard P, Torp-Pedersen C, Aasbjerg K. Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study. Eur J Prev Cardiol 2017;24(14):1498-1505.
36. Zuccarello E, Acquarone E, Calcagno E, et al. Development of novelphosphodiesterase 5 inhibitors for the therapy of Alzheimer’s disease. Biochem Pharmacol 2020;176:113818.
37. Zhang L, Seo JH, Li H, Nam G, Yang HO. The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage. Br J Pharmacol 2018;175:3347-60.
38. Roustit M, Giai J, Gaget O, et al. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann Intern Med 2018;169:694-703.
39. Anand A, Srivastava N, Barwad P, Ramakrishnan S, Roy A, Bhargava B. Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors. Int J Cardiol 2014;174:574-8.
40. Holt A, Blanche P, Jensen AKG, et al. Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study. Ann Intern Med 2022;175:774-82.
41. Pofi R, Giannetta E, Feola T, et al. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med 2022;14:eabl8503.